This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Age: 18 years - 66+
Gender: All
We've found 1 total result for "Urologic Neoplasms".